Resalis Therapeutics
PrivateLast Round
Strategic
Oct 28, 2024
Total Funding Raised
$21.71M
Company Overview
Resalis Therapeutics operates in Healthcare & Life Sciences and is based in Turin. Its latest recorded funding round was a Strategic round in October 2024.
Resalis Therapeutics is a biotechnology company developing non-coding RNA-based therapies for metabolic disorders such as obesity and fatty liver disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Resalis Therapeutics Comparables
Compare Resalis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AptamiR Therapeutics | 87% | |
| Rivus Pharmaceuticals | 78% | |
| EraCal Therapeutics | 75% |
For institutional investors. Book with your work email.
Resalis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Oct 28, 2024 | ||||
| Series A | Jan 4, 2024 | ||||
| Seed | Feb 22, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Resalis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Club degli Investitori | Seed, Series A |
| Claris Ventures | Series A, Seed |
| Sunstone Life Science Ventures | Series A |
| Italian Angels for Growth | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 28, 2024
Sanofi led a strategic funding round.
- Jan 4, 2024
$11M round led by Sunstone Life Science Ventures.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 2, 2026
Resalis Therapeutics S.r.l. appoints Diana M. Røpcke as Chief Medical Officer in Italy on Sep 2nd '26, where she leads clinical strategy and execution.
For institutional investors. Book with your work email.
Resalis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Resalis Therapeutics's valuation, stock price, and market status.
Is Resalis Therapeutics a public or private company?
Resalis Therapeutics is a private company.
What is the current stock price of Resalis Therapeutics?
Resalis Therapeutics is a private company, so its shares have no public market price. Caplight tracks Resalis Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Resalis Therapeutics worth (valuation)?
Valuation information for Resalis Therapeutics is not publicly available.
Can I buy Resalis Therapeutics stock?
Resalis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Resalis Therapeutics's last funding round?
Resalis Therapeutics's most recent funding round was Strategic on October 28, 2024.
Who are the main investors in Resalis Therapeutics?
Key investors in Resalis Therapeutics include Claris Ventures, Sunstone Life Science Ventures.
Will Resalis Therapeutics IPO soon?
No public IPO plans have been announced for Resalis Therapeutics.
How can I track Resalis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Resalis Therapeutics's shares on secondary markets.